2021 AACC Annual Scientific Meeting to Require Both Proof of COVID-19 Vaccination and Negative Test from All In-Person Attendees
|
By LabMedica International staff writers Posted on 31 Aug 2021 |

Illustration
The 2021 American Association for Clinical Chemistry (AACC; Washington, DC, USA) Annual Scientific Meeting & Clinical Lab Expo will be a live event with new location and dates, backed by plans to make the meeting a safe and productive one amidst the flare up in the COVID-19 pandemic.
This year's AACC Annual Scientific Meeting, held in partnership with the Canadian Society of Clinical Chemists, has moved from Anaheim to Atlanta due to stringent COVID-19 lockdown requirements in California, and the meeting dates have also moved by one week to September 26-30. In his latest email, AACC 2021 President Dr. Stephen Master, PhD, had outlined the extensive health and safety planning to make this year’s AACC Annual Scientific Meeting and Clinical Lab Expo in Atlanta a safe and productive in-person meeting. In order to ensure the safety of all attendees, the email clearly stated that unvaccinated people would not be permitted into the conference and expo campus without a current, negative SARS-CoV-2 antigen test or verified proof of vaccination.
As per its latest update, AACC now requires all meeting participants to be vaccinated, and for all meeting participants to have received a negative PCR or antigen COVID-19 test within 72 hours of arriving at the convention center. Proof of COVID-19 vaccination AND proof of a negative PCR or antigen coronavirus test will be required for in-person attendees of the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo. Individuals who are unable to provide both of these things will not be permitted to enter the meeting and antibody test results will not be accepted.
Additionally, mask policies will be in place and strictly enforced. All persons within the AACC meeting campus must wear a face mask covering their nose and mouth at all times they are indoors. Moreover, detailed meeting logistics and design have been laid down to prevent crowding and disperse crowding at the event, and additional measures may be taken if required. Signage will be used to encourage social distancing, plexiglass separations will be placed at points of sale, and educational session times will be staggered to reduce the number of attendees in common areas.
“Our plans to hold a safe and productive in-person meeting in Atlanta have not changed,” wrote Dr. Stephen Master. “The meeting is on, and it will be safe.”
“I encourage you to check out the conference program if you haven’t already. And I look forward to seeing many of you in Atlanta next month,” he added.
Related Links:
American Association for Clinical Chemistry
This year's AACC Annual Scientific Meeting, held in partnership with the Canadian Society of Clinical Chemists, has moved from Anaheim to Atlanta due to stringent COVID-19 lockdown requirements in California, and the meeting dates have also moved by one week to September 26-30. In his latest email, AACC 2021 President Dr. Stephen Master, PhD, had outlined the extensive health and safety planning to make this year’s AACC Annual Scientific Meeting and Clinical Lab Expo in Atlanta a safe and productive in-person meeting. In order to ensure the safety of all attendees, the email clearly stated that unvaccinated people would not be permitted into the conference and expo campus without a current, negative SARS-CoV-2 antigen test or verified proof of vaccination.
As per its latest update, AACC now requires all meeting participants to be vaccinated, and for all meeting participants to have received a negative PCR or antigen COVID-19 test within 72 hours of arriving at the convention center. Proof of COVID-19 vaccination AND proof of a negative PCR or antigen coronavirus test will be required for in-person attendees of the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo. Individuals who are unable to provide both of these things will not be permitted to enter the meeting and antibody test results will not be accepted.
Additionally, mask policies will be in place and strictly enforced. All persons within the AACC meeting campus must wear a face mask covering their nose and mouth at all times they are indoors. Moreover, detailed meeting logistics and design have been laid down to prevent crowding and disperse crowding at the event, and additional measures may be taken if required. Signage will be used to encourage social distancing, plexiglass separations will be placed at points of sale, and educational session times will be staggered to reduce the number of attendees in common areas.
“Our plans to hold a safe and productive in-person meeting in Atlanta have not changed,” wrote Dr. Stephen Master. “The meeting is on, and it will be safe.”
“I encourage you to check out the conference program if you haven’t already. And I look forward to seeing many of you in Atlanta next month,” he added.
Related Links:
American Association for Clinical Chemistry
Latest AACC 2021 News
- Study Showing Differing COVID-19 Antibody Profiles Among Vaccinated and Naturally Infected Individuals Presented at AACC 2021
- Study Reveals Varying Antibody Responses and Adverse Reactions Among Recipients of Different COVID-19 Vaccines
- Novel Study on Performance of Coronavirus Tests in Children Presented at 2021 AACC Annual Scientific Meeting
- New Rapid Test That Identifies Deteriorating COVID-19 Patients with Greater Accuracy than Existing Tests Presented at AACC 2021
- New Blood Test for Occupational Stress Identifies Healthcare Professionals Burned out from COVID-19 Pandemic
- New Non-Invasive Saliva Test for Early and Accurate Detection of Prostate Cancer Presented at AACC 2021
- New Non-Invasive Blood Test for Colon Cancer Presented at 2021 AACC Annual Scientific Meeting
- Study Establishing Accurate Reference Intervals for Pregnant Patients Presented at AACC 2021
- New Test that Measures Antibodies in Girls Who Have Received HPV Vaccine Presented at AACC 2021
- Novel Insights on COVID-19 Vaccines and Virus Evolution, AI in the Clinic, and Miniaturization of Diagnostic Platforms Explored at AACC 2021
- Seegene Unveils New STARlet-AIOS All-in-One Solution for All Molecular Testing at AACC 2021
- Group K Diagnostics Demonstrates KromaHealth Kit that Enables Lab-Quality Results at Point-of-Care
- NGeneBio Showcases NGS-Based Oncology/Genetic Diseases Kits and NGenePlex nCoV qRT-PCR Kit Against COVID-19
- Visby Medical Presents New Portable PCR COVID-19 Test Kit at 2021 AACC Annual Scientific Meeting & Clinical Lab Expo
- Fluxergy Introduces First-of-Its-Kind Multi-Modal Laboratory Platform That Diagnoses COVID-19 On-Site in 60 Minutes
- Mammoth Biosciences Presents AACC 2021 Disruptive Technology Award Finalist CRISPR-Based Detection Platform
Channels
Clinical Chemistry
view channel
Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation
Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more
Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms
Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read moreMolecular Diagnostics
view channel
Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary
Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Blood Test Enables Early Detection and Classification of Glioma
High-grade gliomas, particularly glioblastoma, are fast-growing brain tumors that are often diagnosed late and typically require invasive procedures for confirmation. Current pathways rely on symptoms,... Read more
Multi-Biomarker Blood Test Detects Early-Stage Cancers Across Types
Abbott is showcasing its Cancerguard multi-cancer early detection (MCED) test at the American Association for Cancer Research (AACR) Annual Meeting 2026, where new data highlight continued progress in... Read more
New Sample-to-Answer PCR System Supports High-Throughput Infectious Disease Testing
Clinical laboratories face mounting demand for rapid, high‑volume molecular testing for infectious diseases, including routine monitoring in immunocompromised patients. Consolidated, sample‑to‑answer workflows... Read moreHematology
view channel
Prognostic Biomarker Identified in Diffuse Large B-Cell Lymphoma
Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma and often presents with aggressive clinical behavior. Although many patients respond to standard chemotherapy with... Read more
Routine Blood Test Parameters Link Anemia to Cancer Risk and Mortality
Anemia detected in routine care can signal underlying pathology and is frequently encountered in adults. Because it is defined by hemoglobin levels below the normal range, it is often evaluated with red... Read moreImmunology
view channel
Immune Aging Clock Quantifies Immunosenescence and Identifies Therapeutic Target
Immune aging undermines host defense and contributes to multiple age-related diseases, yet its heterogeneity complicates measurement and intervention. Clinical laboratories increasingly seek objective... Read more
Study Finds Influenza Often Undiagnosed in Winter Deaths
Seasonal influenza drives substantial excess mortality, yet its contribution is often obscured when infections go undiagnosed near the time of death. Many deaths occur outside hospitals or in older adults... Read moreMicrobiology
view channel
Gut Microbiome Test Predicts Melanoma Recurrence After Surgery
Melanoma remains prone to relapse even after surgery and adjuvant immunotherapy, with 25% to 40% of patients experiencing recurrence. Clinicians lack reliable pre-treatment indicators to identify those... Read more
Rapid Blood-Culture Susceptibility Panel Expands Coverage for Gram-Negative Infections
Gram-negative bloodstream infections and sepsis demand fast, precise antimicrobial therapy, yet conventional susceptibility workflows can delay targeted treatment. Clinical laboratories need platforms... Read morePathology
view channel
AI Pathology Model Predicts Immunotherapy Response in Lung Cancer
Clinicians face persistent challenges identifying which patients with metastatic non-small cell lung cancer will benefit from immunotherapy, even as these agents transform oncology care.... Read more
AI Precision Tests Deliver Cancer Risk Insights from Routine H&E Slides
Reliable prognostic profiling and biomarker screening are essential to guide oncology treatment decisions, while laboratories must balance speed and resource constraints. Earlier identification of high‑risk... Read moreTechnology
view channel
AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
Advanced bowel cancer remains difficult to treat, and many patients receive targeted therapies that do not help them but still cause harm. Clinicians need reliable ways to identify likely responders before... Read more
Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
Pre-analytical variation remains a leading source of inconsistent molecular test results and added costs, particularly when laboratories rely on multiple instruments and protocols. Standardizing nucleic... Read moreIndustry
view channel
QuidelOrtho Adds Ultra-Fast PCR Platform with LEX Acquisition
QuidelOrtho Corporation has completed the acquisition of LEX Diagnostics for approximately USD 100 million in cash. The transaction adds the LEX VELO System to QuidelOrtho’s portfolio. The platform received U.... Read more
Seegene Showcases Real-Time PCR Data Analytics Platform at ESCMID
Seegene introduced STAgora, a real-time data analytics platform built on aggregated statistical testing data, at ESCMID Global 2026 in Munich, where it also presented an enhanced model of its automated... Read more
Roche Affiliate Expands MRD Portfolio with SAGA Acquisition
Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more









